| Year |
Citation |
Score |
| 2020 |
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, ... ... Mosse C, et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 185-217. PMID 32023533 DOI: 10.6004/Jnccn.2020.0006 |
0.375 |
|
| 2020 |
Patel DA, Gopalakrishnan R, Engelhardt BG, McArthur E, Sengsayadeth S, Culos KA, Byrne M, Goodman S, Savani BN, Chinratanalab W, Jagasia M, Mosse CA, Cornell RF, Kassim AA. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation. PMID 31992845 DOI: 10.1038/S41409-020-0791-Y |
0.301 |
|
| 2019 |
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, ... ... Mosse C, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 12-20. PMID 30659125 DOI: 10.6004/Jnccn.2019.0002 |
0.346 |
|
| 2018 |
Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research. 65: 67-73. PMID 29310020 DOI: 10.1016/J.Leukres.2017.12.012 |
0.324 |
|
| 2018 |
Mosse CA, Fitzhenry F, LeNoue-Newton M, Lynch JA, Lynch KE, Chang J, Perkins AM, Matheny M, Levy MA. Impact of age on utilization and prognostic value of FLT3 and NPM1 testing in acute myeloid leukemia. Journal of Clinical Oncology. 36: e19008-e19008. DOI: 10.1200/Jco.2018.36.15_Suppl.E19008 |
0.3 |
|
| 2017 |
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, ... ... Mosse C, et al. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1414-1427. PMID 29118233 DOI: 10.6004/Jnccn.2017.0165 |
0.35 |
|
| 2015 |
Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplantation. PMID 26191950 DOI: 10.1038/Bmt.2015.164 |
0.33 |
|
| 2015 |
Salazar KL, Mosse C. Normal Karyotype in a Case of Acute Myeloid Leukemia With Monocytic Differentiation and Hemophagocytosis by Leukemic Blasts Labmedicine. 46: 64-68. PMID 25617396 DOI: 10.1309/Lmudi1L6Pu0Myhsl |
0.32 |
|
| 2015 |
Cornell RF, Jones JE, Mosse CA, Chen H, Dugger L, Goorha S, Chinratanalab W, Engelhardt B, Goodman SA, Greer JP, Lacy S, Kassim AA, McDonagh K, Savani BN, Sengsayadeth S, et al. In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant Blood. 126: 5493-5493. DOI: 10.1182/Blood.V126.23.5493.5493 |
0.345 |
|
| 2014 |
Seegmiller AC, Wasserman A, Kim AS, Kressin MK, Marx ER, Zutter MM, Mosse CA. Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms. Leukemia & Lymphoma. 55: 601-5. PMID 23876099 DOI: 10.3109/10428194.2013.801470 |
0.328 |
|
| 2013 |
Kassim A, McDuffie JS, Mosse CA, Savani BN, Greer JP, Oluwole OO, Goodman S, Engelhardt BG, Chinratanalab W, Kim AS, Jagasia MH. Minimal residual disease (MRD) status pre- and post- high-dose therapy/autologous stem (HDC/ASCT) cell transplantation for multiple myeloma (MM) in the era of novel agents. Journal of Clinical Oncology. 31: 8605-8605. DOI: 10.1200/Jco.2013.31.15_Suppl.8605 |
0.314 |
|
| 2013 |
Dueber JC, Mosse C, Alford CE, Head D, Kressin M. Precursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia Journal of Hematopathology. 6: 161-165. DOI: 10.1007/S12308-012-0168-2 |
0.333 |
|
| 2012 |
Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 1790-9. PMID 22626785 DOI: 10.1016/J.Bbmt.2012.05.009 |
0.355 |
|
| 2011 |
McClintock-Treep SA, Briggs RC, Shults KE, Flye-Blakemore LA, Mosse CA, Jagasia MH, Shinar AA, Dupont WD, Stelzer GT, Head DR. Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow. American Journal of Clinical Pathology. 135: 380-5. PMID 21350091 DOI: 10.1182/Blood.V114.22.1754.1754 |
0.367 |
|
| 2011 |
Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Sinkfield KJ, Santoro SA, Zutter MM. Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy Blood. 118: 2073-2073. DOI: 10.1182/Blood.V118.21.2073.2073 |
0.318 |
|
| 2009 |
Greer JP, Mosse CA. Natural killer-cell neoplasms. Current Hematologic Malignancy Reports. 4: 245-52. PMID 20425414 DOI: 10.1007/S11899-009-0032-3 |
0.311 |
|
| 2009 |
Mosse CA, Stumph JR, Best DH, Vnencak-Jones CL. A B-cell lymphoma diagnosed in "floater" tissue: implications of the diagnosis and resolution of a laboratory error. The American Journal of the Medical Sciences. 338: 248-51. PMID 19745614 DOI: 10.1097/Maj.0B013E3181A88Dc0 |
0.304 |
|
| Show low-probability matches. |